- In April 2023, Medtronic plc launched its next-generation extended-wear insulin infusion set in select markets, offering up to seven days of use. This innovation is aimed at improving patient convenience and reducing the frequency of device changes for individuals with diabetes. The product reflects Medtronic’s continued focus on advancing drug delivery systems for chronic conditions and enhancing patient adherence through wearable technologies
- In March 2023, Amgen Inc. announced the global expansion of its Neulasta Onpro kit, a wearable injector designed to deliver pegfilgrastim automatically after chemotherapy. The move supports the growing shift toward at-home cancer care and reinforces Amgen’s leadership in self-administered drug-device combinations for oncology patients, enhancing both comfort and clinical outcomes
- In March 2023, Insulet Corporation received expanded regulatory approval for its Omnipod 5 Automated Insulin Delivery System across multiple regions, including Europe. The system features smartphone connectivity and adaptive algorithms, representing a major step in integrating digital health with drug delivery for personalized diabetes management
- In February 2023, Ypsomed AG partnered with a major pharmaceutical firm to co-develop a next-generation autoinjector platform. This partnership emphasizes the growing demand for customizable, patient-centric combination products that enable self-injection therapies for conditions such as rheumatoid arthritis and multiple sclerosis
- In January 2023, Teva Pharmaceuticals collaborated with Digital Health Technologies to integrate sensor-enabled smart inhalers into its respiratory therapy portfolio. This development aims to provide real-time data on medication adherence and usage patterns, supporting better disease management and reducing healthcare costs associated with asthma and COPD
